(0.41%) 5 038.76 points
(0.49%) 38 089 points
(0.65%) 15 708 points
(0.00%) $79.00
(4.50%) $2.02
(-0.10%) $2 308.60
(0.43%) $26.86
(0.60%) $960.65
(0.28%) $0.936
(0.33%) $11.07
(0.28%) $0.801
(-1.37%) $91.98
Live Chart Being Loaded With Signals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States...
Stats | |
---|---|
今日成交量 | 110 659 |
平均成交量 | 319 362 |
市值 | 85.96M |
EPS | $0 ( 2024-03-13 ) |
下一个收益日期 | ( $-0.0700 ) 2024-05-09 |
Last Dividend | $0.0150 ( 2015-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | 3.71 |
ATR14 | $0.0110 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Keutzer Timothy | Buy | 239 731 | Common Stock |
2024-02-02 | Keutzer Timothy | Sell | 30 971 | Common Stock |
2024-02-02 | Mahadevia Ankit | Sell | 63 795 | Common Stock |
2024-02-01 | Joseph Tamara L | Buy | 239 731 | Common Stock |
2024-02-02 | Joseph Tamara L | Sell | 30 906 | Common Stock |
INSIDER POWER |
---|
59.47 |
Last 96 transactions |
Buy: 6 234 250 | Sell: 2 240 393 |
音量 相关性
Spero Therapeutics Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Spero Therapeutics Inc 相关性 - 货币/商品
Spero Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $96.74M |
毛利润: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2023 |
营收: | $96.74M |
毛利润: | $96.37M (99.62 %) |
EPS: | $0.430 |
FY | 2022 |
营收: | $48.58M |
毛利润: | $47.03M (96.82 %) |
EPS: | $-1.280 |
FY | 2021 |
营收: | $18.26M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.91 |
Financial Reports:
No articles found.
Spero Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2010-03-30 |
Last Dividend | $0.0150 | 2015-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 2015-10-07 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $0.285 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.93 | -- |
Div. Sustainability Score | 7.56 | |
Div.Growth Potential Score | 0.433 | |
Div. Directional Score | 3.99 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.240 | 1.500 | 5.19 | 7.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.130 | 1.200 | 5.66 | 6.79 | [0 - 0.3] |
returnOnEquityTTM | 0.339 | 1.500 | 7.34 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.53 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.05 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0304 | -1.500 | 9.49 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -20.59 | 1.000 | -8.74 | -8.74 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.311 | -0.623 | [0 - 20] |
debtEquityRatioTTM | 0.0519 | -1.500 | 9.79 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.811 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.200 | 1.000 | 8.00 | 8.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.95 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.542 | 0.800 | 9.72 | 7.78 | [0.5 - 2] |
Total Score | 7.56 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.45 | 1.000 | 9.75 | 0 | [1 - 100] |
returnOnEquityTTM | 0.339 | 2.50 | 8.29 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.623 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.623 | 2.00 | -0.208 | -0.415 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0403 | 1.500 | -3.06 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.334 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.433 |
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。